NATCO Pharma Limited (NATCOPHARM) Stock Forecast & Price Target

Compare

10 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NATCOPHARM Analyst Ratings

Moderate Sell

0 Buy

0 Hold

1 Sell

Based on 1 analysts giving stock ratings to

NATCO

Pharma Limited

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NATCOPHARM Stock 12 Month Forecast

Average Price Target

₹810.00

▼(-6.62% Downside)

Based on 1 Wall Street analysts offering 12 month price targets for NATCO Pharma Limited in the last 3 months. The average price target is ₹810.00 with a high forecast of ₹810.00 and a low forecast of ₹810.00. The average price target represents a -6.62% change from the last price of ₹867.40.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"809":"₹809","1530":"₹1,530","989.25":"₹989.3","1169.5":"₹1,169.5","1349.75":"₹1,349.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":810,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹810.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":810,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹810.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":810,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹810.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[809,989.25,1169.5,1349.75,1530],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Feb<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,924.23,915.4430769230769,906.6561538461539,897.8692307692307,889.0823076923077,880.2953846153846,871.5084615384616,862.7215384615384,853.9346153846154,845.1476923076923,836.3607692307693,827.5738461538461,818.7869230769231,{"y":810,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,924.23,915.4430769230769,906.6561538461539,897.8692307692307,889.0823076923077,880.2953846153846,871.5084615384616,862.7215384615384,853.9346153846154,845.1476923076923,836.3607692307693,827.5738461538461,818.7869230769231,{"y":810,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,924.23,915.4430769230769,906.6561538461539,897.8692307692307,889.0823076923077,880.2953846153846,871.5084615384616,862.7215384615384,853.9346153846154,845.1476923076923,836.3607692307693,827.5738461538461,818.7869230769231,{"y":810,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":991.08,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1190.22,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1349.94,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1529.15,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1393.24,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1395.88,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1409.13,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1393.09,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1171.04,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1171.04,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":849,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":930.96,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":924.23,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target₹810.00

Average Price Target₹810.00

Lowest Price Target₹810.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Abdulkader Puranwala

ICICI Securities

₹890→₹810

Sell

-6.62%

Downside

Reiterated

08/14/25

NATCO Pharma Limited (NATCOPHARM) Receives a Sell from ICICI Securities

Bryce Generon

TR | OpenAI - 4o

₹1,109→₹1,086

Buy

25.20%

Upside

Reiterated

07/26/25

AI Generated ArticleAI Generated Article

Rashmi Sancheti

Dolat Capital

₹1,458→₹913

Sell

5.26%

Upside

Downgraded

02/14/25

Dolat Capital Downgrades Natco Pharma Ltd (NTCPH:IN) to Sell (4)Dolat Capital analyst Rashmi Shetty downgraded Natco Pharma Ltd (NTCPH:IN) from Reduce (3) to Sell (4) with a price target of INR913.00 (from INR1,458.00).

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Abdulkader Puranwala

ICICI Securities

₹890→₹810

Sell

-6.62%

Downside

Reiterated

08/14/25

NATCO Pharma Limited (NATCOPHARM) Receives a Sell from ICICI Securities

Bryce Generon

TR | OpenAI - 4o

₹1,109→₹1,086

Buy

25.20%

Upside

Reiterated

07/26/25

AI Generated ArticleAI Generated Article

Rashmi Sancheti

Dolat Capital

₹1,458→₹913

Sell

5.26%

Upside

Downgraded

02/14/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering NATCO Pharma Limited

1 Month

xxx

Success Rate

1/2 ratings generated profit

Average Return

+5.15%

reiterated a xxx

rating 15 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +5.15% per trade.

3 Months

xxx

Success Rate

1/2 ratings generated profit

Average Return

+5.15%

reiterated a xxx

rating 15 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +5.15% per trade.

1 Year

Abdulkader PuranwalaICICI Securities

Success Rate

1/2 ratings generated profit

Average Return

+5.15%

reiterated a sell rating 15 days ago

Copying Abdulkader Puranwala's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +5.15% per trade.

2 Years

xxx

Success Rate

1/2 ratings generated profit

Average Return

+5.15%

reiterated a xxx

rating 15 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +5.15% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NATCOPHARM Analyst Recommendation Trends

Rating

Feb 25

May 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NATCOPHARM has received 4 Buy Ratings, 1 Hold Ratings, and 2 Sell Ratings. NATCOPHARM average Analyst price target in the past 3 months is 810.00.

Each month's total comprises the sum of three months' worth of ratings.

NATCOPHARM Financial Forecast

NATCOPHARM Earnings Forecast

Next quarter’s earnings estimate for NATCOPHARM is ₹24.70 with a range of ₹24.70 to ₹24.70. The previous quarter’s EPS was ₹26.90. NATCOPHARM beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.17% of the time in the same period. In the last calendar year NATCOPHARM has Outperformed its overall industry.

NATCOPHARM Sales Forecast

Next quarter’s sales forecast for NATCOPHARM is ₹12.04B with a range of ₹12.04B to ₹12.04B. The previous quarter’s sales results were ₹13.29B. NATCOPHARM beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 46.91% of the time in the same period. In the last calendar year NATCOPHARM has Outperformed its overall industry.

NATCOPHARM Stock Forecast FAQ

What is IN:NATCOPHARM’s average 12-month price target, according to analysts?

Based on analyst ratings, NATCO Pharma Limited’s 12-month average price target is 810.00.

What is IN:NATCOPHARM’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for IN:NATCOPHARM, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is NATCO Pharma Limited a Buy, Sell or Hold?

NATCO Pharma Limited has a consensus rating of Moderate Sell, which is based on 0 buy ratings, 0 hold ratings and 1 sell ratings.

What is NATCO Pharma Limited’s share price target?

The average share price target for NATCO Pharma Limited is 810.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is ₹810.00 ,and the lowest forecast is ₹810.00. The average share price target represents -6.62% Decrease from the current price of ₹867.4.

What do analysts say about NATCO Pharma Limited?

NATCO Pharma Limited’s analyst rating consensus is a Moderate Sell. This is based on the ratings of 1 Wall Streets Analysts.

How can I buy shares of NATCO Pharma Limited?

To buy shares of IN:NATCOPHARM, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

NATCO Pharma Limited (NATCOPHARM) Stock Forecast & Price Target

NATCOPHARM Analyst Ratings

NATCOPHARM Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering NATCO Pharma Limited

NATCOPHARM Analyst Recommendation Trends

NATCOPHARM Financial Forecast

NATCOPHARM Earnings Forecast

NATCOPHARM Sales Forecast

NATCOPHARM Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts